These novel medications , Semaglutide , represent a significant advancement in addressing type 2 diabetes and conceivably other conditions . They are categorized as GLP-1 receptor agonists , signifying they function to replicate the natural GLP-1 peptide, enhancing metabolic secretion and suppres